Get the Stockscreener App
44.31
3.23%
-1.5395
Akero Therapeutics Inc stock is traded at $44.31, with a volume of 140.18K.
It is down -3.23% in the last 24 hours and down -9.87% over the past month.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
See More
Previous Close:
$45.85
Open:
$45.44
24h Volume:
140.18K
Relative Volume:
0.12
Market Cap:
$3.63B
Revenue:
-
Net Income/Loss:
$-237.22M
P/E Ratio:
-11.72
EPS:
-3.78
Net Cash Flow:
$-212.64M
1W Performance:
+1.60%
1M Performance:
-9.87%
6M Performance:
+62.29%
1Y Performance:
+58.63%
1-Day Range:
$44.13
$45.95
1-Week Range:
$41.15
$47.11
52-Week Range:
$17.86
$58.40
Akero Therapeutics Inc Stock (AKRO) Company Profile
Name
Akero Therapeutics Inc
Sector
Industry
Phone
650-487-6488
Address
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
Compare AKRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AKRO
Akero Therapeutics Inc
|
44.20 | 3.63B | 0 | -237.22M | -212.64M | -3.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.00 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
685.15 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
578.42 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.21 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.40 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-27-25 | Reiterated | H.C. Wainwright | Buy |
| Nov-18-24 | Initiated | Citigroup | Buy |
| Apr-22-24 | Resumed | BofA Securities | Neutral |
| Sep-19-23 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-28-23 | Initiated | UBS | Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-14-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| Feb-26-21 | Initiated | Guggenheim | Buy |
| Sep-10-20 | Initiated | Morgan Stanley | Overweight |
| Jul-20-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-07-20 | Initiated | Chardan Capital Markets | Buy |
| Jul-01-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-02-20 | Initiated | H.C. Wainwright | Buy |
| Feb-10-20 | Initiated | Canaccord Genuity | Buy |
| Jul-15-19 | Initiated | Evercore ISI | Outperform |
| Jul-15-19 | Initiated | JP Morgan | Overweight |
| Jul-15-19 | Initiated | Jefferies | Buy |
| Jul-15-19 | Initiated | ROTH Capital | Buy |
View All
Akero Therapeutics Inc Stock (AKRO) Latest News
Akero Therapeutics CEO Andrew Cheng sells $1.25 million in stock - Investing.com India
Proficio Capital Partners LLC Acquires Shares of 11,490 Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Timothy Rolph Sells 12,500 Shares - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives Average Rating of "Buy" from Analysts - MarketBeat
Q1 EPS Estimate for Akero Therapeutics Boosted by Analyst - MarketBeat
Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Sells 50,000 Shares of Stock - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Sells $48,090.00 in Stock - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Stake Decreased by Y Intercept Hong Kong Ltd - MarketBeat
Trading (AKRO) With Integrated Risk Controls - Stock Traders Daily
Akero therapeutics chief scientific officer sells $556,590 in stock By Investing.com - Investing.com Australia
Akero therapeutics chief scientific officer sells $556,590 in stock - Investing.com
Akero Therapeutics, Inc. (NASDAQ:AKRO) Short Interest Update - MarketBeat
HC Wainwright Issues Optimistic Estimate for AKRO Earnings - Defense World
Akero Therapeutics (NASDAQ:AKRO) Given New $75.00 Price Target at HC Wainwright - MarketBeat
Akero Therapeutics senior VP sells $48,090 in stock By Investing.com - Investing.com South Africa
Boston Pharma Plays Catch Up To Akero, 89bio In MASH - Citeline News & Insights
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Stockholders to Learn More About the Investigation - Markets Insider
Akero Therapeutics senior VP sells $48,090 in stock - Investing.com India
Akero Therapeutics Executives Sell Shares - TradingView
Akero therapeutics COO Jonathan Young sells $2.24 million in stock By Investing.com - Investing.com UK
Y Intercept Hong Kong Ltd Has $249,000 Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
Akero Therapeutics, Inc. (NASDAQ:AKRO) Short Interest Up 32.0% in February - Defense World
Akero Therapeutics (NASDAQ:AKRO) Announces Quarterly Earnings Results, Misses Estimates By $0.01 EPS - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Investors to Inquire about Securities Investigation - Markets Insider
Is Agilon Health (AGL) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Akero Therapeutics stock target raised to $75 by H.C. Wainwright - Investing.com India
Akero Therapeutics, Inc. (NASDAQ:AKRO) Stake Lifted by Rhumbline Advisers - Defense World
Why Akero Therapeutics, Inc. (AKRO) is Skyrocketing So Far in 2025 - MSN
Akero Therapeutics (AKRO) to Release Earnings on Friday - MarketBeat
Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
Akero Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Akero Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
3 Mid-Caps Worth Watching Closely in March - MarketBeat
Akero Therapeutics, Inc. SEC 10-K Report - TradingView
Akero Therapeutics Q4 Loss Unchanged -February 28, 2025 at 07:27 am EST - Marketscreener.com
Earnings Flash (AKRO) Akero Therapeutics Posts Q4 Total Operating Expenses $78M - Marketscreener.com
Earnings Flash (AKRO) Akero Therapeutics Posts Q4 Loss $-0.99 Per Share, vs. FactSet Est of $-1.14 - Marketscreener.com
Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides - The Bakersfield Californian
Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire
Can Akero's Breakthrough Cirrhosis Reversal Results Reshape MASH Treatment Landscape? - StockTitan
IMMINENT AKRO DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Akero Therapeutics, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
Is Akero Therapeutics Inc. (AKRO) the Best Performing Mid Cap Stock to Buy According to Analysts? - MSN
Akero Therapeutics (AKRO) Projected to Post Quarterly Earnings on Thursday - Defense World
Madrigal’s Rezdiffra Continues Its Solid Launch - Scrip
Akero Stock Hits Over 18-Month High On MASH Trial Data: Citi Lauds ‘Best-Case Scenario,’ Retail Exuberant - MSN
10 Best Performing Mid Cap Stocks to Buy According to Analysts - Insider Monkey
Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells 10,000 Shares of Stock - MarketBeat
Akero Therapeutics Inc Stock (AKRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Akero Therapeutics Inc Stock (AKRO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Rolph Timothy | Chief Scientific Officer |
Mar 05 '25 |
Option Exercise |
21.10 |
12,500 |
263,750 |
182,737 |
| Rolph Timothy | Chief Scientific Officer |
Mar 05 '25 |
Sale |
44.53 |
12,500 |
556,590 |
170,237 |
| Young Jonathan | Chief Operating Officer |
Mar 04 '25 |
Sale |
44.86 |
50,000 |
2,243,213 |
201,147 |
| Lamy Patrick | Senior VP, Commercial Strategy |
Mar 03 '25 |
Option Exercise |
19.87 |
1,000 |
19,870 |
34,492 |
| Lamy Patrick | Senior VP, Commercial Strategy |
Mar 03 '25 |
Sale |
48.09 |
1,000 |
48,090 |
33,492 |
| Yale Catriona | Chief Development Officer |
Feb 18 '25 |
Option Exercise |
21.10 |
10,000 |
211,000 |
105,648 |
| Yale Catriona | Chief Development Officer |
Feb 18 '25 |
Sale |
49.87 |
10,000 |
498,660 |
95,648 |
| Cheng Andrew | President and CEO |
Feb 10 '25 |
Sale |
52.73 |
30,000 |
1,581,994 |
686,062 |
| Graham G. Walmsley | Director |
Jan 30 '25 |
Buy |
48.00 |
200,000 |
9,600,000 |
1,000,000 |
| Rolph Timothy | Chief Scientific Officer |
Feb 05 '25 |
Option Exercise |
21.10 |
18,750 |
395,625 |
188,987 |
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):